EP 2512448 B1 20160706 - PHARMACEUTICAL ORAL DOSAGE FORM CONTAINING A SYNTHETIC OLIGOSACCHARIDE
Title (en)
PHARMACEUTICAL ORAL DOSAGE FORM CONTAINING A SYNTHETIC OLIGOSACCHARIDE
Title (de)
PHARMAZEUTISCHE ORALE DOSISFORM, DIE EIN SYNTHETISCHES OLIGOSACCHARID ENTHÄLT
Title (fr)
FORME GALÉNIQUE ORALE PHARMACEUTIQUE CONTENANT UN OLIGOSACCHARIDE SYNTHÉTIQUE
Publication
Application
Priority
- EP 09306271 A 20091218
- EP 2010070117 W 20101217
- EP 10795361 A 20101217
Abstract (en)
[origin: WO2011073408A2] The present invention concerns a pharmaceutical formulation intended for oral administration containing a synthetic oligosaccharides containing one to 18 monosaccharide units and having a therapeutical activity or a pharmaceutically acceptable additions salt or solvate thereof wherein the formulation contains: a) the synthetic oligosaccharide (A) in an amount of up to 5% by weight of the total weight of the formulation, advantageously up to 1 % by weight of the total weight of the formulation, b) a lipophilic phase (B) consisting of triglyceride of fatty acids in an amount of 50 to 80% by weight of the total weight of the formulation, advantageously of 50 to 70 % by weight of the total weight of the formulation, c) at least one lipophilic surfactant (C) with HLB below 7 consisting of partial esters of polyol and fatty acids in an amount of 10 to 30% by weight of the total weight of the formulation, advantageously of 15 to 30 % by weight of the total weight of the formulation, d) at least one hydrophilic surfactant (D) with HLB above 7 in an amount of up to 20% by weight of the total weight of the formulation, advantageously up to 15% by weight of the total weight of the formulation, e) optionally, at least one hydrophilic solvent (E) in an amount of up to 15% by weight of the total weight of the formulation, advantageously up to 10% by weight of the total weight of the formulation, f) between 0 and 30% by weight of the total weight of the formulation of a chemical and/or physical stabilization agent (F), advantageously between 0 and 20 % by weight of the total weight of the formulation, wherein when the formulation is in a form of a reverse emulsion or microemulsion and contains at least one hydrophilic solvent (E), the physical stabilization agent is present and is silicon dioxide.
IPC 8 full level
A61K 9/107 (2006.01); A61K 9/48 (2006.01); A61K 31/702 (2006.01)
CPC (source: EP US)
A61K 9/107 (2013.01 - EP US); A61K 9/4891 (2013.01 - EP US); A61K 31/702 (2013.01 - EP US); A61P 7/02 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2011073408 A2 20110623; WO 2011073408 A3 20120315; AR 079561 A1 20120201; AU 2010332797 A1 20120705; AU 2010332797 B2 20150528; BR 112012015016 A2 20170620; BR 112012015016 A8 20171010; BR 112012015016 B8 20210525; CA 2784529 A1 20110623; CA 2784529 C 20180522; CN 102892411 A 20130123; CN 102892411 B 20150121; EP 2512448 A2 20121024; EP 2512448 B1 20160706; JP 2013514336 A 20130425; JP 2016041735 A 20160331; JP 6109574 B2 20170405; US 2012316132 A1 20121213; US 9259389 B2 20160216
DOCDB simple family (application)
EP 2010070117 W 20101217; AR P100104784 A 20101220; AU 2010332797 A 20101217; BR 112012015016 A 20101217; CA 2784529 A 20101217; CN 201080057013 A 20101217; EP 10795361 A 20101217; JP 2012543798 A 20101217; JP 2015216910 A 20151104; US 201013515965 A 20101217